Table 7Results of one way sensitivity analysis

Model parameterRanges of values usedResulting ICERs corresponding to the lowest and highest values used
Rivastigmine Dose3–12mgAChEI dominates – £307
Resource use estimates associated with management of non-cognitive symptoms
Days per year in residential care for users134.40–369.60AChEI dominates – £687
Improvement243.90–334.08£611 – AChEI dominates
Non-improvement
Days per year in hospital care for users2.08–9.92£57 – £214
Improvement6.12–17.88£278 – AChEI dominates
Non-improvement
Hours per week in home care for users15.12–26.88AChEI dominates – £358
Improvement19.12–30.88£533 – AChEI dominates
Non-improvement
GP visits per year for users5.42–7.78£107 – £164
Improvement8.05–13.15£197 – £74
Non-improvement
Hours per week in day care for users4.32–35.68AChEI dominates – £273
Improvement10.08–17.92£187 – £84
Non-improvement
Plus assumption:
No difference in resource use between improvement and non-improvement states£3,179
Resource use associated with follow-up monitoring of AChEI treatment
Geriatric follow-up outpatient appointment2 every 20 weeks£1,023
Rest monitoring (regarding blood tests, weight and blood pressure measurements, ECG)undertaken in every 20-week cycle£388
Plus combination of the above two scenarios£1,273
Resource use and incidence of side effects
Additional GP home visits for side effect monitoring4£196
RR of incidence of side effects of AChEI treatment relative to no AChEI treatment2£414
Plus combination of the above two scenarios£748
Transition probabilities per 20 week cycle
Non- improvement to improvement with no AchEI treatment -prior to adjustment for mortality0.182–0.402£583 – AChEI dominates
RR of improvement of AChEI treatment vs no AChEI treatment1.05–2.77£34,751 – AChEI dominates
Remaining in the improvement state0.000–1.000£775 – £725
Mortality rate0.058–0.151£211 – £52
Discount Rate for costs and outcomes0–6%£155 – £123

From: APPENDIX 17, ECONOMIC ANALYSIS OF THE USE OF ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF NON-COGNITIVE SYMPTOMS OF DEMENTIA WITH LEWY BODIES

Cover of Dementia
Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care.
NICE Clinical Guidelines, No. 42.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2007.
Copyright © 2007, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.